InVivo Therapeutics Announces Posting Of Management Presentation Recording From Annual Shareholders Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the posting of the management presentation recording from the 2015 Annual Shareholders Meeting held on June 16th, 2015. The recording is available on the investor relations page of InVivo’s website - http://www.invivotherapeutics.com/investor-relations/annual-meeting/.
“It was rewarding to report on the progress InVivo has made in the last year. I’m pleased with the support and feedback we received from our shareholders and look forward to continued, transparent communications”
“It was rewarding to report on the progress InVivo has made in the last year. I’m pleased with the support and feedback we received from our shareholders and look forward to continued, transparent communications,” said Mark Perrin, InVivo’s Chief Executive Officer and Chairman.
About the Neuro-Spinal Scaffold
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an Investigational Device Exemption (IDE) pilot study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this
press release that do not describe historical facts may constitute
forward-looking statements within the meaning of the federal securities
laws. These statements can be identified by words such as
"believe," "anticipate," "intend," "estimate,"
"will," "may," "should," "expect," “designed to,” “potentially,” and
similar expressions, and include statements regarding the company’s cash
position, its ability to conduct a pivotal probable benefit study, the
expected enrollment of additional patients in its pilot study, the
company’s planned clinical development programs within and outside the
United States and the company’s ability to obtain patent protection for
its intellectual property. Any forward-looking statements contained
herein are based on current expectations, and are subject to a number of
risks and uncertainties. Factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the company’s ability to
successfully open additional clinical sites for enrollment and to enroll
additional patients; the timing of the Institutional Review Board
process; the company’s ability to obtain FDA approval to modify its
pilot trial protocol or to conduct a future pivotal study; the company’s
ability to commercialize its products; the company’s ability to protect
its intellectual property and to develop, market and sell products based
on its technology; the expected benefits and efficacy of the company’s
products and technology in connection with the treatment of spinal cord
injuries; the availability of substantial additional funding for the
company to continue its operations and to conduct research and
development, clinical studies and future product commercialization; and
other risks associated with the company’s business, research, product
development, regulatory approval, marketing and distribution plans and
strategies identified and described in more detail in the company’s
Annual Report on Form 10-K for the year ended December 31, 2014, and its
other filings with the SEC, including the company’s Form 10-Qs and
current reports on Form 8-K. The company does not undertake to update
these forward-looking statements.
Contacts
InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor
Relations
bluque@invivotherapeutics.com